Cargando…
Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy
BACKGROUND: Pancreatic carcinoma is a significant cause of cancer-related death in developed countries. As the level of circulating endothelial cells (CECs) is known to increase in response to various cancers, we investigated the predictive potential of CEC levels and the association of these levels...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437212/ https://www.ncbi.nlm.nih.gov/pubmed/22731825 http://dx.doi.org/10.1186/1471-2407-12-268 |
_version_ | 1782242763989843968 |
---|---|
author | Kondo, Shunsuke Ueno, Hideki Hashimoto, Jun Morizane, Chigusa Koizumi, Fumiaki Okusaka, Takuji Tamura, Kenji |
author_facet | Kondo, Shunsuke Ueno, Hideki Hashimoto, Jun Morizane, Chigusa Koizumi, Fumiaki Okusaka, Takuji Tamura, Kenji |
author_sort | Kondo, Shunsuke |
collection | PubMed |
description | BACKGROUND: Pancreatic carcinoma is a significant cause of cancer-related death in developed countries. As the level of circulating endothelial cells (CECs) is known to increase in response to various cancers, we investigated the predictive potential of CEC levels and the association of these levels with the expression of proangiogenic factors in pancreatic carcinoma patients. METHODS: Pancreatic carcinoma patients receiving gemcitabine chemotherapy were prospectively assigned to this study. CEC levels were measured using the CellTracks system, and the plasma levels of several angiogenesis factors were measured using multiplex immunoassay. Associations between clinical outcomes and the levels of these factors were evaluated. RESULTS: Baseline CEC levels were markedly higher in pancreatic carcinoma patients (n = 37) than in healthy volunteers (n = 53). Moreover, these high CEC levels were associated with decreased overall survival (median, 297 days versus 143 days, P < 0.001) and progression-free survival (median, 150 days versus 64 days, P = 0.008), as well as with high vascular endothelial growth factor, interleukin (IL)-8, and IL-10 expression in the pancreatic carcinoma patients. CONCLUSIONS: Several chemokines and proangiogenic factors correlate with the release of CECs, and the number of CECs detected may be a useful prognostic marker in pancreatic carcinoma patients undergoing gemcitabine chemotherapy. TRIAL REGISTRATION: UMIN000002323 |
format | Online Article Text |
id | pubmed-3437212 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-34372122012-09-09 Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy Kondo, Shunsuke Ueno, Hideki Hashimoto, Jun Morizane, Chigusa Koizumi, Fumiaki Okusaka, Takuji Tamura, Kenji BMC Cancer Research Article BACKGROUND: Pancreatic carcinoma is a significant cause of cancer-related death in developed countries. As the level of circulating endothelial cells (CECs) is known to increase in response to various cancers, we investigated the predictive potential of CEC levels and the association of these levels with the expression of proangiogenic factors in pancreatic carcinoma patients. METHODS: Pancreatic carcinoma patients receiving gemcitabine chemotherapy were prospectively assigned to this study. CEC levels were measured using the CellTracks system, and the plasma levels of several angiogenesis factors were measured using multiplex immunoassay. Associations between clinical outcomes and the levels of these factors were evaluated. RESULTS: Baseline CEC levels were markedly higher in pancreatic carcinoma patients (n = 37) than in healthy volunteers (n = 53). Moreover, these high CEC levels were associated with decreased overall survival (median, 297 days versus 143 days, P < 0.001) and progression-free survival (median, 150 days versus 64 days, P = 0.008), as well as with high vascular endothelial growth factor, interleukin (IL)-8, and IL-10 expression in the pancreatic carcinoma patients. CONCLUSIONS: Several chemokines and proangiogenic factors correlate with the release of CECs, and the number of CECs detected may be a useful prognostic marker in pancreatic carcinoma patients undergoing gemcitabine chemotherapy. TRIAL REGISTRATION: UMIN000002323 BioMed Central 2012-06-25 /pmc/articles/PMC3437212/ /pubmed/22731825 http://dx.doi.org/10.1186/1471-2407-12-268 Text en Copyright ©2012 Kondo et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Kondo, Shunsuke Ueno, Hideki Hashimoto, Jun Morizane, Chigusa Koizumi, Fumiaki Okusaka, Takuji Tamura, Kenji Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy |
title | Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy |
title_full | Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy |
title_fullStr | Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy |
title_full_unstemmed | Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy |
title_short | Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy |
title_sort | circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3437212/ https://www.ncbi.nlm.nih.gov/pubmed/22731825 http://dx.doi.org/10.1186/1471-2407-12-268 |
work_keys_str_mv | AT kondoshunsuke circulatingendothelialcellsandotherangiogenesisfactorsinpancreaticcarcinomapatientsreceivinggemcitabinechemotherapy AT uenohideki circulatingendothelialcellsandotherangiogenesisfactorsinpancreaticcarcinomapatientsreceivinggemcitabinechemotherapy AT hashimotojun circulatingendothelialcellsandotherangiogenesisfactorsinpancreaticcarcinomapatientsreceivinggemcitabinechemotherapy AT morizanechigusa circulatingendothelialcellsandotherangiogenesisfactorsinpancreaticcarcinomapatientsreceivinggemcitabinechemotherapy AT koizumifumiaki circulatingendothelialcellsandotherangiogenesisfactorsinpancreaticcarcinomapatientsreceivinggemcitabinechemotherapy AT okusakatakuji circulatingendothelialcellsandotherangiogenesisfactorsinpancreaticcarcinomapatientsreceivinggemcitabinechemotherapy AT tamurakenji circulatingendothelialcellsandotherangiogenesisfactorsinpancreaticcarcinomapatientsreceivinggemcitabinechemotherapy |